Common Contracts
2 similar Successor Agent Agreement and Amendment No. 9 to Third Amended and Restated Credit and Guaranty Agreement contracts by Valeant Pharmaceuticals International, Inc.
EXECUTION VERSION SUCCESSOR AGENT AGREEMENT AND AMENDMENT NO. 9 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENTSuccessor Agent Agreement and Amendment No. 9 to Third Amended and Restated Credit and Guaranty Agreement • May 5th, 2020 • New York
This SUCCESSOR AGENT AGREEMENT is dated as of January 8, 2015 (this “Agreement”) by and among BARCLAYS BANK PLC (“Barclays”), GOLDMAN SACHS LENDING PARTNERS LLC (“GSLP”), in its capacities as the Administrative Agent, Collateral Agent and Swing Line Lender (in such capacities, the “Existing Agent”) under the Credit Agreement (as defined below) for the Lenders (as defined below), the Requisite Lenders, VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the laws of the Province of British Columbia (the “Borrower”), and the Guarantors.
SUCCESSOR AGENT AGREEMENT AND AMENDMENT NO. 9 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENTSuccessor Agent Agreement and Amendment No. 9 to Third Amended and Restated Credit and Guaranty Agreement • February 25th, 2015 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This SUCCESSOR AGENT AGREEMENT is dated as of January 8, 2015 (this “Agreement”) by and among BARCLAYS BANK PLC (“Barclays”), GOLDMAN SACHS LENDING PARTNERS LLC (“GSLP”), in its capacities as the Administrative Agent, Collateral Agent and Swing Line Lender (in such capacities, the “Existing Agent”) under the Credit Agreement (as defined below) for the Lenders (as defined below), the Requisite Lenders, VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the laws of the Province of British Columbia (the “Borrower”), and the Guarantors.
